胸腺肽α1联合阿帕替尼治疗原发性肝癌的疗效观察  

Efficacy of thymosinα1 combined with apatinib for primary liver cancer

作　　者：崔丹桂 陈悠 于彤波 CUI Dan-gui;HEN You;YU Tong-bo(Department of Pharmacy,Xi'an Emergency Center,Xi'an 710018,China;Department of Pharmacy,The Eighth Hospital of Xi'an,Xi'an 710061,China;Department of Laboratory,Xi'an Eighth Hospital,Xi'an 710061,China)

机构地区：[1]陕西省西安急救中心医务科,西安710018 [2]西安市第八医院药剂科,西安710061 [3]西安市第八医院检验科,西安710061

出　　处：《中国肿瘤临床与康复》2021年第10期1200-1203,共4页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨胸腺肽α1联合阿帕替尼治疗原发性肝癌(PHC)经导管肝动脉化疗栓塞术(TACE)后患者血清天冬氨酸氨基转移酶(AST)、总胆红素(TBIL)及Th1细胞水平变化。方法选取2019年1月至2020年5月间西安急救中心收治的行TACE治疗的125例PHC患者,采用随机数表法分为研究组64例和对照组61例。术后研究组患者采用胸腺肽α1联合阿帕替尼治疗,对照组患者采用阿帕替尼治疗,比较两组患者术前、治疗3个月后血清AST、谷丙氨酸氨基转移酶(ALT)、TBIL、T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))及Th1型细胞因子[白细胞介素-12(IL-12)、干扰素-γ(INF-γ)和肿瘤坏死因子-α(TNF-α)]水平。结果术前,两组患者AST、ALT和TBIL水平比较,差异无统计学意义(P>0.05);治疗3个月后,两组患者AST、ALT和TBIL水平均降低,且研究组均低于对照组,差异均有统计学意义(均P<0.05)。术前,两组患者CD3^(+)、CD4^(+)、CD8^(+)和CD4^(+)/CD8^(+)水平比较,差异无统计学意义(P>0.05);治疗3个月后,两组患者各项水平均改善,且研究组患者CD3^(+)、CD4^(+)和CD4^(+)/CD8^(+)水平均高于对照组,CD8^(+)水平低于对照组,差异均有统计学意义(均P<0.05)。术前,两组患者IL-12、INF-γ及TNF-α水平比较,差异无统计学意义(P>0.05);治疗3个月后,两组患者IL-12、INF-γ及TNF-α水平均升高,且研究组高于对照组,差异均有统计学意义(均P<0.05)。结论PHC患者TACE后采用胸腺肽α1联合阿帕替尼治疗,可有效改善患者血清AST、TBIL及Th1细胞水平,帮助患者肝功能恢复,提高免疫功能,值得推广应用。Objective To study the changes in serum aspartate aminotransferase(AST)and total bilirubin(TBIL)and Th1 cell levels in patients with primary liver cancer(PHC)undergoing transcatheter hepatic artery chemoembolization(TACE)on thymosinα1 combined with apatinib.Methods A total of 125 patients with PHC who underwent TACE treatment at The Eighth Hospital of Xi'an were selected from January 2019 to May 2020.They were assigned to an experimental group(64 patients)and a control group(61 patients).After the surgery,experimental group received thymosinα1 combined with apatinib and the control group only received apatinib.Levels of AST,glutalanine aminotransferase(ALT),TBIL,T lym-phocyte subsets including CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)and Th1 cytokines including interleukin-12(IL-12),interferon-γ(INF-γ)and tumor necrosis factor-α(TNF-α)were compared before the surgery and at 3 months after the treatment.Results There was no significantly difference in the preoperative AST,ALT,and TBIL levels between the two groups before the surgery(P>0.05).At 3 months after the treat-ment,AST,ALT,and TBIL levels decreased in both groups compared with those before the treatment with the experimental group lower than the control group(all P<0.05).Similarly,there was no significant difference in the levels of CD3^(+),CD4^(+),CD8^(+)and CD4^(+)/CD8^(+)between the two groups before the opera-tion(P>0.05).After the treatment,the above levels were significantly improved in the two groups com-pared with those before the operation and the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)were higher in the experimental group had than the control group and the levels of CD8^(+)were lower than in the control group(all P<0.05).There was no significant difference in the levels of IL-12,INF-γand TNF-αbetween the two groups before surgery(P>0.05).After the treatment,the levels of IL-12,INF-γand TNF-αwere in-creased in the two groups compared with those before the surgery with these levels higher in the experimental group than in the control g

关 键 词：原发性肝肿瘤 TACE 胸腺肽Α1 阿帕替尼 

分 类 号：R735.7[医药卫生—肿瘤]